ATE518539T1 - Verwendung von kondensierten pyrimidinderivaten zur behandlung von autoimmun- und entzündungserkrankungen - Google Patents

Verwendung von kondensierten pyrimidinderivaten zur behandlung von autoimmun- und entzündungserkrankungen

Info

Publication number
ATE518539T1
ATE518539T1 AT08716828T AT08716828T ATE518539T1 AT E518539 T1 ATE518539 T1 AT E518539T1 AT 08716828 T AT08716828 T AT 08716828T AT 08716828 T AT08716828 T AT 08716828T AT E518539 T1 ATE518539 T1 AT E518539T1
Authority
AT
Austria
Prior art keywords
autoimmune
treatment
inflammatory diseases
pyrimidine derivatives
nhr
Prior art date
Application number
AT08716828T
Other languages
English (en)
Inventor
Dan Stoicescu
Original Assignee
Dan Stoicescu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dan Stoicescu filed Critical Dan Stoicescu
Application granted granted Critical
Publication of ATE518539T1 publication Critical patent/ATE518539T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08716828T 2007-02-14 2008-02-13 Verwendung von kondensierten pyrimidinderivaten zur behandlung von autoimmun- und entzündungserkrankungen ATE518539T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102410A EP1958632A1 (de) 2007-02-14 2007-02-14 Kondensierte Pyrimidinderivaten zur Behandlung von Entzündungserkrankungen und Autoimmunerkrankungen
PCT/EP2008/051731 WO2008098957A1 (en) 2007-02-14 2008-02-13 Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE518539T1 true ATE518539T1 (de) 2011-08-15

Family

ID=38016693

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08716828T ATE518539T1 (de) 2007-02-14 2008-02-13 Verwendung von kondensierten pyrimidinderivaten zur behandlung von autoimmun- und entzündungserkrankungen

Country Status (15)

Country Link
US (1) US8247422B2 (de)
EP (2) EP1958632A1 (de)
JP (1) JP2010518143A (de)
AT (1) ATE518539T1 (de)
AU (1) AU2008214687B2 (de)
CA (1) CA2677588C (de)
CY (1) CY1112480T1 (de)
DK (1) DK2117552T3 (de)
ES (1) ES2369035T3 (de)
HR (1) HRP20110663T1 (de)
NZ (1) NZ578897A (de)
PL (1) PL2117552T3 (de)
PT (1) PT2117552E (de)
SI (1) SI2117552T1 (de)
WO (1) WO2008098957A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1754484A1 (de) * 2005-08-17 2007-02-21 Dan Stoicescu Kondensierte Pyrimidinderivative als Inhibitoren der Folsäure-abhängiger Enzyme
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
CN103656073A (zh) * 2013-12-12 2014-03-26 黄根强 一种治疗结节性多动脉炎的中药

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) * 1950-06-20 Substituted pteridines and method
US4079056A (en) * 1975-03-31 1978-03-14 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of making pteridine compounds
CH630380A5 (de) 1977-08-12 1982-06-15 Lonza Ag Verfahren zur herstellung von l-methotrexat.
GB2070607A (en) 1980-03-04 1981-09-09 Sandoz Ltd 1-(3,5- Ditrifluoromethylphenyl)-5- phenyl-1,2,3-triazole derivatives useful as plant growth regulating agents
US4684653A (en) * 1985-03-08 1987-08-04 The Trustees Of Princeton University Pyrido(2,3-d)pyrimidine derivatives
JPS63218666A (ja) 1987-03-09 1988-09-12 Mitsubishi Kasei Corp ピリダジノン誘導体またはその塩類
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
GB9013615D0 (en) 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
AUPP751398A0 (en) * 1998-12-04 1999-01-07 Commonwealth Scientific And Industrial Research Organisation Methotrexate derivatives
US20060083681A1 (en) * 2004-10-18 2006-04-20 Ajay Purohit Compounds for myocardial perfusion imaging
DE102004057594A1 (de) * 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
EP1754484A1 (de) * 2005-08-17 2007-02-21 Dan Stoicescu Kondensierte Pyrimidinderivative als Inhibitoren der Folsäure-abhängiger Enzyme
JP5440934B2 (ja) * 2006-05-24 2014-03-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換プテリジン

Also Published As

Publication number Publication date
EP1958632A1 (de) 2008-08-20
US8247422B2 (en) 2012-08-21
CY1112480T1 (el) 2015-12-09
HRP20110663T1 (hr) 2011-10-31
PL2117552T3 (pl) 2012-02-29
US20100160329A1 (en) 2010-06-24
SI2117552T1 (sl) 2011-11-30
CA2677588A1 (en) 2008-08-21
EP2117552B1 (de) 2011-08-03
DK2117552T3 (da) 2011-11-21
AU2008214687A1 (en) 2008-08-21
AU2008214687B2 (en) 2012-11-08
PT2117552E (pt) 2011-10-11
ES2369035T3 (es) 2011-11-24
CA2677588C (en) 2013-11-19
NZ578897A (en) 2011-03-31
EP2117552A1 (de) 2009-11-18
WO2008098957A1 (en) 2008-08-21
JP2010518143A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
CY1109734T1 (el) Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης
ATE390421T1 (de) Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
EA200700099A1 (ru) Производные пиридина
CA2443950A1 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
RU2004130488A (ru) Пиримидиновые производные
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
ATE517882T1 (de) Chinolinderivate
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
RU2013130256A (ru) Новые циклоспориновые производные для лечения и предупреждения вирусных инфекций
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
ECSP066948A (es) Benzoxazinas para el tratamiento de enfermedades de las vías respiratorias
RU2010118454A (ru) Модуляторы метаботропного глутаматного рецептора для лечения болезни паркинсона
JP2018527324A5 (de)
ATE518539T1 (de) Verwendung von kondensierten pyrimidinderivaten zur behandlung von autoimmun- und entzündungserkrankungen
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
ATE384714T1 (de) Pyrazolderivate
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
DE60319254D1 (de) Pyrazolamide zur behandlung von hiv-infektionen
RU2009148601A (ru) Применение ингибиторов гда для лечения деструкции костной ткани
HRP20080194T3 (en) Condensed pyrimidine derivatives as inhibitors of folic acid-dependent enzymes
ATE391122T1 (de) 4 ((2,4-dichloro-5-methoxyphenyl)amino)-6-alkoxy- 7-ethynyl-3-quinolinecarbonitrile zur behandlung von ischämie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2117552

Country of ref document: EP